Join the Urothelial Carcinoma group to help and get support from people like you.
Urothelial Carcinoma News
NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
WEDNESDAY, May 8, 2024 – For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) response and outcomes,...
FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
FRIDAY, April 26, 2024 – The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients wit...
Urine Test Could Cut Need for Painful Bladder Cancer Procedure
MONDAY, April 8, 2024 – A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn’t come back, researchers report. People who’ve got...
Drug Combo Marks Advance Against Bladder Cancer
MONDAY, March 11, 2024 – A cancer drug duo more than doubled the survival of people battling the most common form of advanced bladder cancer, trial results show. Patients who took a combo of meds...
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with ...
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 – For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly better survival than...
U.S. Food and Drug Administration Grants Full Approval for Balversa to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Balversa® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations Phase 3 THOR ...
Too Few Cancer Patients Get Palliative Care When Urinary Blockages Arise
THURSDAY, Dec. 28, 2023 – The prognosis is poor for many cancer patients who develop serious urinary blockages, but researchers say less than half receive palliative care. Palliative care aims to...
Erdafitinib Improves Survival in Metastatic Urothelial Cancer With FGFR Mutation
MONDAY, Oct. 23, 2023 – For patients with metastatic urothelial carcinoma and FGFR alterations with progression after previous treatment with anti-programmed cell death protein 1 (PD-1) or a...
Treatment Strategy Helps People With Advanced Bladder Cancer Retain the Organ
TUESDAY, Oct. 10, 2023 – “Listen, I’m not a Pollyanna,” New Yorker David Cabelis makes clear. “I’m a cab driver.” “But I was diagnosed with this cancer,” the 72-year old said. “Bladder cancer, that’s...
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 – For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published...
Urine-Based DNA Methylation Test Can Detect Bladder Cancer
MONDAY, Aug. 21, 2023 – A urine-based DNA methylation test can accurately detect bladder cancer in patients with hematuria, according to a study published online June 14 in The Journal of Molecular...
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
U.S. Food and Drug Administration Approves Opdivo (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) August 20, 2021 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for...
U.S. FDA Grants Regular Approval and Expands Indication for Padcev (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously...
Ask a question
To post your own question to this support group, sign in or create an account.